CN108602877A - 区分全长高分子量激肽原（hmwk）和裂解的hmwk的肽定量测定法 - Google Patents

区分全长高分子量激肽原（hmwk）和裂解的hmwk的肽定量测定法 Download PDF

Info

Publication number
CN108602877A
CN108602877A CN201680079865.9A CN201680079865A CN108602877A CN 108602877 A CN108602877 A CN 108602877A CN 201680079865 A CN201680079865 A CN 201680079865A CN 108602877 A CN108602877 A CN 108602877A
Authority
CN
China
Prior art keywords
hmwk
peptide
sample
seq
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680079865.9A
Other languages
English (en)
Chinese (zh)
Inventor
吴江
张国栋
丹尼尔·J·塞克斯顿
R·福塞特
G·M·穆斯塔法
M·塞韦克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of CN108602877A publication Critical patent/CN108602877A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8831—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G01N2800/224—Haemostasis or coagulation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Enzymes And Modification Thereof (AREA)
CN201680079865.9A 2015-12-15 2016-12-15 区分全长高分子量激肽原（hmwk）和裂解的hmwk的肽定量测定法 Pending CN108602877A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562267734P 2015-12-15 2015-12-15
US62/267,734 2015-12-15
PCT/US2016/066936 WO2017106504A1 (en) 2015-12-15 2016-12-15 Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk

Publications (1)

Publication Number Publication Date
CN108602877A true CN108602877A (zh) 2018-09-28

Family

ID=57794352

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680079865.9A Pending CN108602877A (zh) 2015-12-15 2016-12-15 区分全长高分子量激肽原（hmwk）和裂解的hmwk的肽定量测定法

Country Status (13)

Country Link
US (3) US11668718B2 (enExample)
EP (2) EP3390439B1 (enExample)
JP (3) JP7092669B2 (enExample)
KR (2) KR102874711B1 (enExample)
CN (1) CN108602877A (enExample)
AU (3) AU2016372159B2 (enExample)
CA (1) CA3008621A1 (enExample)
CO (1) CO2018007216A2 (enExample)
EA (1) EA201891414A1 (enExample)
IL (4) IL322971A (enExample)
MX (2) MX2018007493A (enExample)
NZ (1) NZ743482A (enExample)
WO (1) WO2017106504A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
PT3060908T (pt) 2013-10-21 2021-05-27 Dyax Corp Diagnóstico e tratamento de doenças autoimunes
DK3365685T3 (da) 2015-10-19 2021-03-01 Dyax Corp Immunoassay til påvisning af spaltet højmolekylært kininogen
CO2018007216A2 (es) 2015-12-15 2018-09-20 Dyax Corp Ensayo de cuantificacion de peptido para diferenciar quininogeno de alto peso molecular (hmwk) de longitud completa y hmwk escindido
WO2018225830A1 (ja) * 2017-06-08 2018-12-13 国立大学法人宮崎大学 肺がんの検出方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047323A (en) * 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
WO2015061183A1 (en) * 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers
CN105073778A (zh) * 2013-01-20 2015-11-18 戴埃克斯有限公司 缓激肽介导的病症的评估和治疗

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2603487B2 (ja) 1987-11-26 1997-04-23 大日本製薬株式会社 ガンに罹患している疑いのあるヒトをスクリーニングする方法
JPH08208692A (ja) 1994-09-28 1996-08-13 Sumitomo Pharmaceut Co Ltd 新規な細胞接着抑制ペプチド誘導体
JP3073439B2 (ja) 1996-02-08 2000-08-07 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
WO2000027415A2 (en) 1998-11-10 2000-05-18 Temple University - Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by peptide analogs of high molecular weight kininogen domain 5
US20060154319A1 (en) 1999-04-29 2006-07-13 Flodgaard Hans J Inhibition of bradykinin release
EP1227842A4 (en) 1999-11-12 2005-06-08 Univ Temple INHIBITION OF ANGIOGENESIS BY ANTIBODIES WITH KININOGEN OF HIGH MOLECULAR WEIGHT OF DOMAIN 5
WO2003077872A2 (en) 2002-03-15 2003-09-25 Attenuon, Llc Cell surface tropomyosin as a target of angiogenesis inhibition
CN1858243A (zh) 2005-04-30 2006-11-08 安徽省生物医学研究所 一种预测血管紧张素ii受体拮抗剂类降压药药物作用的方法及其应用
EP2216651A4 (en) * 2007-10-18 2010-12-01 Miyazaki Prefectural Ind Suppo BIOMARKERS FOR THE DIAGNOSIS OF LIVER DISEASE
AU2009269257A1 (en) * 2008-07-07 2010-01-14 Nippon Zoki Pharmaceutical Co., Ltd. Method for detection of fibromyalgia
GB0821721D0 (en) 2008-11-27 2008-12-31 Hansa Medical Ab Antimicrobial therapy
EP2770327B1 (en) 2009-03-30 2017-06-14 Nordic Bioscience A/S Fibrosis biomarker assay
JP5714285B2 (ja) * 2010-09-29 2015-05-07 株式会社プロトセラ 妊娠高血圧症候群マーカーおよびそれを用いた診断
CN102558329A (zh) 2010-12-10 2012-07-11 中国人民解放军军事医学科学院生物医学分析中心 一组特异性多肽及其在制备肺癌早期诊断试剂中的用途
EP3246339B1 (en) 2012-03-28 2019-10-09 Sanofi Antibodies to bradykinin b1 receptor ligands
JP2016188761A (ja) 2013-08-23 2016-11-04 国立研究開発法人国立国際医療研究センター 糖尿病腎症の発症または発症リスクの検出方法及びキット
WO2015120036A1 (en) * 2014-02-04 2015-08-13 University Of Virginia Patent Foundation Compositions and methods for analysis of protein sequences and post-translational modifications
CN104345154B (zh) 2014-08-22 2016-10-26 北京蛋白质组研究中心 一种检测多肿瘤相关“多肽-蛋白组合式标志物”的双抗体夹心试剂盒
CN104155457B (zh) 2014-08-22 2016-11-16 北京蛋白质组研究中心 一种结直肠癌相关“多肽-蛋白组合式标志物”检测试剂盒
WO2016081413A1 (en) 2014-11-17 2016-05-26 The Rockefeller University Compositions and methods for use in diagnosis of alzheimer's disease
CO2018007216A2 (es) 2015-12-15 2018-09-20 Dyax Corp Ensayo de cuantificacion de peptido para diferenciar quininogeno de alto peso molecular (hmwk) de longitud completa y hmwk escindido

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047323A (en) * 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
CN105073778A (zh) * 2013-01-20 2015-11-18 戴埃克斯有限公司 缓激肽介导的病症的评估和治疗
WO2015061183A1 (en) * 2013-10-21 2015-04-30 Dyax Corp. Assays for determining plasma kallikrein system biomarkers

Also Published As

Publication number Publication date
CO2018007216A2 (es) 2018-09-20
AU2025200412A1 (en) 2025-02-13
US20230408528A1 (en) 2023-12-21
JP2019505185A (ja) 2019-02-28
AU2022204058A1 (en) 2022-06-30
IL297850B1 (en) 2024-06-01
EP3390439B1 (en) 2025-03-12
US12135329B2 (en) 2024-11-05
EP4597115A3 (en) 2025-08-13
IL297850A (en) 2023-01-01
EP3390439A1 (en) 2018-10-24
US20250172567A1 (en) 2025-05-29
IL259995A (en) 2018-07-31
AU2016372159B2 (en) 2022-03-24
IL259995B1 (en) 2023-01-01
JP2022141640A (ja) 2022-09-29
JP7092669B2 (ja) 2022-06-28
IL312919B1 (en) 2025-10-01
KR102728491B1 (ko) 2024-11-13
AU2022204058B2 (en) 2024-10-31
IL259995B2 (en) 2023-05-01
IL297850B2 (en) 2024-10-01
JP7758766B2 (ja) 2025-10-22
KR20180134838A (ko) 2018-12-19
WO2017106504A8 (en) 2017-07-13
EA201891414A1 (ru) 2019-02-28
JP7425117B2 (ja) 2024-01-30
AU2016372159A1 (en) 2018-07-05
KR20240161708A (ko) 2024-11-12
EP4597115A2 (en) 2025-08-06
IL312919A (en) 2024-07-01
MX2023000773A (es) 2023-02-22
JP2024026847A (ja) 2024-02-28
BR112018012165A2 (pt) 2018-12-04
KR102874711B1 (ko) 2025-10-23
NZ743482A (en) 2023-04-28
MX2018007493A (es) 2018-09-18
US20210025898A1 (en) 2021-01-28
IL322971A (en) 2025-10-01
US11668718B2 (en) 2023-06-06
WO2017106504A1 (en) 2017-06-22
CA3008621A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
JP7758766B2 (ja) 完全長の高分子量キニノーゲン（ｈｍｗｋ）と切断されたｈｍｗｋとを区別するためのペプチド定量アッセイ
O'Riordan et al. Urinary proteomic analysis of chronic allograft nephropathy
Barascuk et al. Development and validation of an enzyme-linked immunosorbent assay for the quantification of a specific MMP-9 mediated degradation fragment of type III collagen—A novel biomarker of atherosclerotic plaque remodeling
JP2019516104A (ja) 子宮内膜がんのマーカーとしてのｍｍｐ９
EP3909509B1 (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
TW202104900A (zh) 定量功能性ｃ１酯酶抑制子（ｆｃ１—ｉｎｈ）之方法
CN113287019A (zh) 亚临床动脉粥样硬化的生物标志物
JP2025188193A (ja) 完全長の高分子量キニノーゲン（ｈｍｗｋ）と切断されたｈｍｗｋとを区別するためのペプチド定量アッセイ
BR112018012165B1 (pt) Método para detectar cininogênio de alto peso molecular (hmwk) clivado, método para diferenciar hmwk completo e hmwk clivado, e método para identificar um sujeito com, ou correndo o risco de ter, angioedema hereditário (hae)
CA3211713A1 (en) Methods for the measurement of protein c and activated protein c
Etwebi MYELOPEROXIDASE INDUCES ENDOTHELIAL DYSFUNCTION VIA ACTIVATION OF THE CALCIUM DEPENDENT PROTEASE CALPAIN
CA2835806A1 (en) Methods and compositions relating to platelet sensitivity
HK40061902B (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
HK1255461B (en) Evacuated blood collection tubes containing protease inhibitors for the assessment of contact system activation
EA040036B1 (ru) Вакуумные пробирки для сбора крови, содержащие ингибиторы протеазы, для оценки активации контактной системы

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210617

Address after: 1-1, sidingmu, xiudaocho, Central District, Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL Co.,Ltd.

Address before: Massachusetts, USA

Applicant before: Daix GmbH

TA01 Transfer of patent application right